En Es
Categories

Industry News

Danaher Acquires Integrated DNA Technologies

By Labmedica International staff writers
13 Mar 2018

Image: Danaher Corporation has entered into a definitive agreement to acquire Integrated DNA Technologies (Photo courtesy of iStock).Danaher Corporation (Washington, D.C, USA) has entered into a definitive agreement to acquire Integrated DNA Technologies (IDT) (Skokie, IL, USA), a privately held provider of high-value consumables for genomics applications in molecular biology, qPCR, next generation sequencing, synthetic biology, gene editing and molecular diagnostics.

IDT develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. The company's primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT will operate as a standalone operating company and brand within Danaher's Life Sciences platform.

"We are thrilled to have IDT join Danaher's Life Sciences platform," said Rainer Blair, Executive Vice President of Danaher's Life Sciences platform. "IDT expands our presence into the highly attractive genomics market and will help play a central role in accelerating our customers' research and time to market as they develop critical diagnostic tests and potential life-saving therapies. IDT's historical double-digit core revenue growth and strong margins are a testament to the team's commitment to the highest standards of quality, service, and technical expertise."

"Danaher is a proven steward of founder-led businesses, such as Hach and Phenomenex. We recognize the extraordinary contributions Dr. Walder and IDT have made to the advancement of genomics research and applications over the past 30 years," said Thomas P. Joyce, Jr., Danaher President and Chief Executive Officer. "We look forward to supporting the IDT team and helping them leverage the tools of the Danaher Business System (DBS) to further enhance their growth profile and continue to create long-term customer value."

"For more than 30 years, IDT's innovative tools and solutions for genomics applications have helped scientists advance their research and contribute to solving some of the world's most vexing diseases and other challenges addressed by the life sciences community," added Joseph Walder, CEO and Chairman of IDT. "Joining Danaher will allow us to accelerate the high pace of innovation and superior service our customers have come to expect from us, as well as help expand our global reach. I'm excited to watch IDT further grow and innovate in this expanding area of genomics with the help of DBS."



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

23 Nov 2018
AI Predicts Alzheimer’s Disease Years before Diagnosis
A new study on the application of deep learning (DL) to detect changes in brain metabolism predictive of Alzheimer’s disease (AD) has found that artificial intelligence (AI) improves the ability of brain imaging to predict AD.
Read More
23 Nov 2018
UK to Set Up New GBP 10 Million Centre for Medical Imaging and AI
The UK’s London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data, to create tools that will help clinicians speed up and improve diagnosis and care across a number of patient pathways, including dementia, heart failure and cancer.
Read More
23 Nov 2018
New AI Algorithm Enhances Polyp Detection in Colonoscopy Procedures
Researchers at Shanghai Wision AI Co., Ltd., a developer of computer-aided diagnostic algorithms and systems to improve the accuracy and effectiveness of diagnostic imaging, have announced results of a study validating a novel machine-learning algorithm that improves detection of adenomatous polyps during colonoscopy. The AI algorithm is built on the same network architecture that is used to develop self-driving cars and is designed to enable “self-driving” in colonoscopy procedures.
Read More
20 Nov 2018
Study Finds AI Falls Short When Analyzing Medical Data
A study conducted at the Icahn School of Medicine at Mount Sinai has found that artificial intelligence (AI) tools trained to detect pneumonia on chest X-rays suffered significant decreases in performance when tested on data from outside health systems. These findings suggest that unless AI in the medical space is carefully tested for performance across a wide range of populations, the deep learning models may not perform as accurately as expected.
Read More
20 Nov 2018
New AI Software for Brain Bleed Diagnosis Receives FDA Clearance
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI, a clinical diagnostics intelligence platform company.
Read More
20 Nov 2018
Global Refurbished Medical Devices Market to Increase by 10% by 2023
The global refurbished medical devices market is expected to grow at a CAGR of over 10% during the forecast period 2019-2023, driven by the organized healthcare ecosystem in the developed economies. Moreover, privatization in the healthcare sector is increasing rapidly due to the inability of governments to invest efficiently in the sector, coupled with high demand for innovation and technology for superior healthcare services.
Read More
12 Nov 2018
ACR Data Science Institute Releases AI Use Cases to Accelerate AI Adoption
The American College of Radiology Data Science Institute has released a first-of-its-kind series of standardized artificial intelligence (AI) use cases that will accelerate medical imaging AI adoption. This continually updated, freely available use case series is the product of a previously missing and collaborative framework that enables efficient creation, implementation and ongoing improvement of radiological AI tools.
Read More
12 Nov 2018
Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics
Siemens Healthineers has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.
Read More
12 Nov 2018
OpenSight Augmented Reality System for Microsoft HoloLens Cleared by FDA
The FDA has granted 510(k) clearance to the OpenSight Augmented Reality System, making it the first AR medical solution for Microsoft HoloLens to be cleared for use in pre-operative surgical planning. Developed by Novarad, a provider of specialized enterprise imaging and workflow solutions, OpenSight renders 2D, 3D and 4D images of patients interactively, while accurately overlaying them directly onto the patient’s body.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions